Sarah Krein Researches Whatever Is Necessary to Improve Veterans’ Care

Most VA researchers begin their research career because of a fascination with a certain clinical subject–a niche area usually discovered early in their studies that starts them off on a long, relatively straight, journey. Not for Sarah Krein, PhD, RN, who is interested in many subjects but none so deeply as the methodology of research itself. 

What Matters in Survival, Treatment of Lymphoid Cancers?

Oncologists balance the most effective treatment against the likelihood of adverse effects for every patient with cancer. Generally, the assumption is that older patients and those with more comorbidities and poorer performance status will experience more negative effects, including potentially fatal toxicity, from aggressive treatment. A study presented at the American Society of Clinical Oncology annual meeting in June calls into question this assumption for at least some patients and specific malignancies.

Choosing the Right Regimen for Elderly Patients with Advanced RCC

Most clinical trials provide limited guidance on the appropriate treatment of patients seen in clinical practice. Particularly in oncology, participants in trials tend to be significantly younger and in substantially better health than the average patient. Renal cell carcinoma (RCC) provides a clear example of the challenge.

nCRC, Sequencing Offers Better Guidance than Staining When Results Differ

Chemotherapy has long been a component in the first-line treatment for advanced or metastatic colorectal cancer (mCRC). A number of studies in recent years indicate that a subset of patients with specific genetic mutations do not respond well to the recommended 5-fluorouracil-based regimens, such as FOLFOX (5-FU, oxaliplatin, and leucovorin) or FOLFIRI (5-FU, irinotecan, and leucovorin) alone or in combination with other agents.